Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Kos Pharmaceuticals, Inc (KOSP)

No earlier versions found for this Subject.

Return to Kos Pharmaceuticals, Inc (KOSP)

Kos Pharmaceuticals, Inc went public today @$20 1/4 per share, closing up 1 3/4.

Description:

Kos Pharmaceuticals develops pharmaceuticals to treat chronic cardiovascular and respiratory diseases. The company's cardiovascular products are primarily controlled-release, once-a-day, oral dosage formulations, while its respiratory products are aerosolized inhalation products. The company has developed Niaspan, an oral drug
composed of niacin, for the treatment of multiple lipid disorders which are associated with coronary heart disease. Kos has agreements with Fuisz Technologies for the development of products using a technology developed by Fuisz. The company also sponsors basic research at Tufts University and Boston University.

Any/all constructive commentary is appreciated.

DD